# Cell Therapy Human Raw Materials Market

> Cell Therapy Human Raw Materials Market Research Report Information By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, [Proteins, Growth Factors, Nucleotides, and Other Supplements], Reagents & Buffers, and Other Raw Materials), By End-User (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, and Academic & Research Institutions), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 22.6%
- **2024:** $ 5.34 Billion
- **2025:** $ 6.55 Billion
- **2035:** $ 50.28 Billion
- **Key Players:** Lonza (CH), Thermo Fisher Scientific (US), Merck KGaA (DE), Fujifilm Diosynth Biotechnologies (JP), Cytiva (US), Miltenyi Biotec (DE), STEMCELL Technologies (CA), Bristol-Myers Squibb (US)

**Report ID:** MRFR/Pharma/19940-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/cell-therapy-human-raw-materials-market-21539

---

## Market Summary

## **Cell Therapy Human Raw Materials Market Overview**

As per MRFR analysis, the Cell Therapy Human Raw Materials Market Size was estimated at 5.34 (USD Billion) in 2024. The Cell Therapy Human Raw Materials Market Industry is expected to grow from 6.55 (USD Billion) in 2025 to 41.01 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 22.60% during the forecast period (2025 - 2034). The rising demand for cell therapies and advancements in biotechnology are the primary drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Cell Therapy Human Raw Materials Market Trends**

### **Growing advancements in manufacturing technologies are driving the market growth.**

Advanced sensors, automation capabilities, and control systems in next-generation bioreactor systems provide for fine control over the environment of the cell culture, maximizing productivity and growth while lowering the danger of contamination. Single-use technologies include disposable bags, tubing assemblies, and bioreactors that eliminate the need for cleaning and sterilizing. This simplifies manufacturing processes and allows for flexible, affordable production at different quantities. In particular, for cell treatments meant for clinical use, closed system processing reduces the need for open operations, enhancing product quality and safety and lowering the danger of contamination.

Automating repetitive operations, improving process consistency, and increasing throughput can include automation and robotics into cell therapy manufacturing processes to minimize human error and save labor expenses.

Cell therapy is expanding due to the growing popularity of regenerative medicine, creating a need for certain raw human resources necessary for the novel medical strategy. Regenerative medicine has attracted much interest and support because it uses cell-based therapies to treat various illnesses and harness the body's healing abilities. This renewed interest is due to the possibility of transforming treatment approaches and offering new treatments for ailments for which few effective treatments exist.

The Keck School of Medicine at USC received a USD 2 million grant from the California Institute of Regenerative Medicine (CIRM) in October 2023 to improve its newly created cGMP Laboratory. This cutting-edge laboratory is intended to promote early-stage investigations into gene and cell therapies that are therapeutically feasible. The development of cutting-edge technological capabilities, efficient operations, and strict protocols required for the successful translation of these medicines from the laboratory to clinical applications is anticipated to be supported by the money from the CIRM grant.

Similarly, in August 2023, researchers at City of Hope were awarded USD 32.3 million by the California Institute for Regenerative Medicine (CIRM) to support three innovative phase 1 clinical trials. These clinical studies evaluate new cell and gene therapy treatments for individuals with severe aplastic anemia, acute myeloid leukemia, and HIV.

Furthermore, an increasing range of raw materials specifically designed for these targeted therapeutic applications is required as cell therapy shows promise in treating ailments other than cancer and conventional indications like autoimmune diseases, neurodegenerative diseases, and cardiovascular conditions. An increase in clinical trials investigating the safety and effectiveness of cell treatments for novel disease targets results from the expansion of indications. The market for raw materials is being driven by the need for large amounts of raw materials for cell culture, expansion, and characterization, which are necessary for these trials. Thus driving the Cell Therapy Human Raw Materials market revenue.

## **Cell Therapy Human Raw Materials Market Segment Insights**

### **Cell Therapy Human Raw Materials Product Insights**

Based on Product, the   Cell Therapy Human Raw Materials market segmentation includes cell culture media, cell culture sera, cell culture supplements, [proteins, growth factors, nucleotides, and other supplements], reagents & buffers, and other raw materials. In 2023, the cell culture supplements segment dominated the market due to the growing need for cell-based medicines that do not involve animals. With initiatives like the development of new products and company expansion, many industry players are actively investigating unexplored prospects in the market. Moreover, the market share of growth factors is the highest among supplements for cell culture.

Supplements for cell culture offer a way to attain serum-free conditions without sacrificing the nutrients and growth elements required for healthy cell growth. For example, a 2020 study described the sequential delivery of growth factors and cytokines released from cryogel, which enhanced tissue regeneration and sped up wound healing.

The cell culture media category is anticipated to be the fastest growing. The specific and regulated environment that cell culture media offers, along with vital nutrients and growth agents, is crucial for the survival and growth of cells. Researchers and manufacturers can optimize parameters in this controlled environment to ensure the repeatability and scalability of cell cultures for therapeutic applications. To improve the efficacy of the cell treatment procedure, many businesses also invest a lot of money in creating cell culture media. For example, Lonza released TheraPEAK T-VIVO Cell Culture Medium in May 2023 to accelerate cell therapy's advancement.

### **Cell Therapy Human Raw Materials End-Use Insights**

Based on End-Use, the   Cell Therapy Human Raw Materials market segmentation includes biopharmaceutical & pharmaceutical companies, CROs & CMOs, and academic & research institutions. In 2023, the biopharmaceutical & pharmaceutical companies category generated the most income. This is attributed to rising R&D expenditures, increased need for cell-based treatments, and the availability of cutting-edge medical facilities. As a result, businesses invest significantly in research and development, utilizing their biotechnology knowledge to find and create innovative cell treatments.

For example, in May 2023, NewBiologix successfully obtained USD 50 million in investment to advance the development of its cutting-edge technology platform to improve the processes involved in manufacturing gene and cell therapies.

The cell therapy human raw materials CROs & CMOs category is predicted to expand quickly over the projected period. [Contract Research Organizations](../../../reports/contract-research-organization-market-3322) (CROs) are a vital resource for preclinical and clinical research. Their competence in trial design, patient recruiting, and regulatory compliance helps to facilitate the development of cell treatments. Conversely, biopharmaceutical businesses lacking the necessary skills might benefit from better and more affordable manufacturing options provided by Contract Manufacturing Organizations (CMOs). Therefore, due to offering extremely specialized services, CROs and CMOs have become important figures in the end-user segment.

**Figure 1:   Cell Therapy Human Raw Materials Market, by End-Use, 2023 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Cell Therapy Human Raw Materials Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Cell Therapy Human Raw Materials market will dominate, owing to the region's dominance, which can be attributed to supportive government policies, an increasing need for innovative treatments, and coordinated efforts by significant industry players to improve cell therapy products that treat a range of chronic illnesses. Furthermore, North America is home to many well-known businesses that produce and sell cell-based products, increasing demand for human raw materials for cell therapy and consequently driving market expansion.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

**Figure 2:   Cell Therapy Human Raw Materials Market Share By Region 2023 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Cell Therapy Human Raw Materials market is the second-largest market share. The European Medicines Agency (EMA) and the Committee for Advanced Therapies (CAT) are two prominent regulatory bodies in Europe with a well-established regulatory framework for cell therapy products. These organizations offer precise criteria and regulatory approval routes. The market launch of cell therapy products is made easier by this regulatory framework that promotes innovation, increasing demand for human raw materials.

Further, the German Cell Therapy Human Raw Materials market held the largest market share, and the UK Cell Therapy Human Raw Materials market was the fastest-growing market in the European region.

The Asia-Pacific Cell Therapy Human Raw Materials Market is expected to grow at the fastest CAGR from 2025 to 2034. This increase is attributed to the growing demand for sophisticated cell therapies and the increased focus on biotechnology. Major industry players' installation of manufacturing facilities, strategic alliances, and heightened R&D activities drive the market's growth. Moreover, China’s Cell Therapy Human Raw Materials market held the largest market share, and the Indian Cell Therapy Human Raw Materials market was the fastest-growing market in the Asia-Pacific region.

## **Cell Therapy Human Raw Materials Key Market Players & Competitive Insights**

Leading industry participants are making significant R&D investments to broaden their product offerings, contributing to the further expansion of the Cell Therapy Human Raw Materials market. In addition, market players are engaging in various strategic endeavors to broaden their worldwide reach. Significant developments in the market include introducing new products, agreements under contracts, mergers and acquisitions, increased investment, and cooperation with other entities. It must provide affordable products for the Cell Therapy Human Raw Materials sector to grow and thrive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers use in the worldwide Cell Therapy Human Raw Materials industry to assist customers and expand the market sector. The Cell Therapy Human Raw Materials sector has recently provided some of the biggest medical benefits.

Major players in the Cell Therapy Human Raw Materials market, including Thermo Fisher Scientific, Inc, ACROBiosystems, STEMCELL Technologies, Merck KGaA, Actylis, RoosterBio, Inc., PromoCell GMBH, Grifols, S.A., Charles River Laboratories, Danaher, Akron Biotech, BioIVT, GeminiBio, AllCells, and CGT  , and others, are attempting to increase market demand by investing in research and development operations.

Science and technology are the focus of Merck KGaA (Merck), a division of E. Merck KG. In addition to developing liquid crystal mixes, organic light-emitting diode (OLED) materials, cosmetic active ingredients, coating pigments, and high-tech materials, it also finds, develops, and produces prescription medications for treating cancer, multiple sclerosis, and infertility. Additionally, Merck offers many products, including flow cytometry kits and instruments, end-to-end systems, test assays, analytical reagents, gene editing tools, cell lines, antibodies, and microbiological and biomonitoring products. The business caters to the markets for performance materials, healthcare, and life sciences.

Merck KGaA invested USD 24.38 million in July 2023 to increase the manufacturing of cell culture medium in the United States. It increased the Lenexa facility's capacity to produce cell culture medium.

Serving the   biotechnology sector, GeminiBio focuses on assisting clients in expediting the development of life-improving biotherapeutics, from fundamental research to commercial production. Regardless of batch size, the company primarily focuses on developing catalog and bespoke cGMP bioprocess liquids that drastically streamline clients' manufacturing workflows. It also specializes in developing cell culture products and solutions that assist customers in streamlining their discovery, development, and production processes. GeminiBio is a California company located in West Sacramento with two manufacturing buildings totaling 57,000 square feet.

The company's cell culture sera and bioprocess liquid manufacturing facilities are divided between animal component and animal origin-free cGMP manufacturing to fulfill the exacting requirements of biotechnology research and production customers. Gemini Bio announced in March 2023 that an advanced cGMP bioprocess liquid manufacturing facility would open its doors in West Sacramento, California. This improved its capacity to satisfy the expanding needs of the markets for cell and gene therapy and biotechnology.

### **Key Companies in the Cell Therapy Human Raw Materials market include**

## Cell Therapy Human Raw Materials Industry Developments

- **Q2 2024: FUJIFILM Irvine Scientific Expands Cell Culture Media Manufacturing Facility in the Netherlands** FUJIFILM Irvine Scientific announced the opening of a new cell culture media manufacturing facility in Tilburg, Netherlands, to support the growing demand for raw materials in cell therapy and regenerative medicine applications.
- **Q2 2024: Lonza Opens New Cell and Gene Therapy Manufacturing Facility in Houston** Lonza inaugurated a new state-of-the-art manufacturing facility in Houston, Texas, dedicated to the production of cell and gene therapy raw materials, aiming to increase capacity for clinical and commercial supply.
- **Q2 2024: Thermo Fisher Scientific Launches Gibco CTS DynaCellect Magnetic Separation System for Cell Therapy Manufacturing** Thermo Fisher Scientific introduced the Gibco CTS DynaCellect Magnetic Separation System, a new product designed to streamline cell therapy manufacturing workflows by improving the separation and processing of human cells.
- **Q3 2024: Bio-Techne Announces Launch of GMP-Grade Recombinant Human Cytokines for Cell Therapy Applications** Bio-Techne launched a new line of GMP-grade recombinant human cytokines, expanding its portfolio of raw materials for use in the manufacturing of cell therapies.
- **Q3 2024: Cytiva and Forecyte Bio Announce Strategic Partnership to Advance Cell Therapy Manufacturing in China** Cytiva and Forecyte Bio entered a strategic partnership to co-develop and supply critical raw materials and technologies for cell therapy manufacturing in the Chinese market.
- **Q3 2024: Sartorius Acquires CellGenix to Strengthen Cell Therapy Raw Materials Portfolio** Sartorius completed the acquisition of CellGenix, a leading supplier of GMP-grade raw materials for cell and gene therapies, to enhance its offerings in the cell therapy sector.
- **Q4 2024: Merck KGaA Invests €100 Million in New Cell Therapy Raw Materials Facility in Switzerland** Merck KGaA announced a €100 million investment to build a new facility in Switzerland dedicated to the production of high-quality raw materials for cell therapy manufacturing.
- **Q4 2024: Miltenyi Biotec Opens Expanded GMP Manufacturing Site for Cell Therapy Reagents in Germany** Miltenyi Biotec opened an expanded GMP manufacturing site in Bergisch Gladbach, Germany, to increase production capacity for cell therapy reagents and raw materials.
- **Q1 2025: Avantor Acquires Cell Solutions Provider BioIVT to Expand Cell Therapy Raw Materials Business** Avantor acquired BioIVT, a provider of biological specimens and cell-based products, to strengthen its position in the cell therapy raw materials market.
- **Q1 2025: Thermo Fisher Scientific Launches GMP-Grade Human Platelet Lysate for Cell Therapy Manufacturing** Thermo Fisher Scientific introduced a new GMP-grade human platelet lysate product, designed to support the expansion and manufacturing of human cell therapies.
- **Q2 2025: Catalent Announces $200 Million Expansion of Cell Therapy Raw Materials Production in Maryland** Catalent announced a $200 million investment to expand its cell therapy raw materials production capabilities at its facility in Maryland, aiming to meet increasing demand from biopharma clients.
- **Q2 2025: Wuxi AppTec Opens New Cell Therapy Raw Materials Manufacturing Facility in Shanghai** Wuxi AppTec opened a new manufacturing facility in Shanghai dedicated to the production of raw materials for cell therapy, expanding its global supply network.

## **Cell Therapy Human Raw Materials Market Segmentation**

### **Cell Therapy Human Raw Materials Product Outlook**

### **Cell Therapy Human Raw Materials End-Use Outlook**

### **Cell Therapy Human Raw Materials Regional Outlook**

**North America**

**Europe**

**Asia-Pacific**

**Rest of the World**

## Market Drivers

### Advancements in Stem Cell Research

Recent advancements in stem cell research are propelling the Cell Therapy Human Raw Materials Market forward. Innovations in understanding stem cell biology and their potential applications in regenerative medicine have opened new avenues for treatment. Research indicates that stem cells can differentiate into various cell types, offering promising solutions for conditions previously deemed untreatable. The market for stem cell-based therapies is projected to grow substantially, with estimates suggesting a compound annual growth rate of over 20% in the coming years. This growth is likely to be fueled by increased investment in research and development, as well as collaborations between academic institutions and biotechnology firms. Consequently, the Cell Therapy Human Raw Materials Market stands to benefit from these scientific breakthroughs, enhancing the availability and efficacy of cell-based therapies.

### Regulatory Support for Cell Therapies

Regulatory bodies are increasingly providing support for the development and commercialization of cell therapies, which is a crucial driver for the Cell Therapy Human Raw Materials Market. Streamlined approval processes and clear guidelines are encouraging companies to invest in cell-based therapies. Recent initiatives by regulatory agencies aim to facilitate faster access to innovative treatments, thereby enhancing patient care. This supportive regulatory environment is likely to stimulate market growth, as companies can navigate the approval landscape more efficiently. Additionally, the establishment of specialized regulatory frameworks for advanced therapies is expected to further bolster the Cell Therapy Human Raw Materials Market. As a result, the alignment of regulatory policies with industry needs may lead to an increase in the availability of cell therapies, ultimately benefiting patients worldwide.

### Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders is a primary driver for the Cell Therapy Human Raw Materials Market. As these conditions become more prevalent, the demand for innovative treatment options rises. Cell therapies, which utilize human raw materials, are gaining traction as effective solutions. According to recent estimates, the global burden of chronic diseases is expected to reach unprecedented levels, necessitating advanced therapeutic interventions. This trend indicates a growing market for cell therapy products, as healthcare providers seek to incorporate these therapies into treatment protocols. The Cell Therapy Human Raw Materials Market is thus positioned to expand significantly, driven by the urgent need for effective therapies that address these complex health challenges.

### Growing Investment in Biopharmaceuticals

The surge in investment within the biopharmaceutical sector is significantly influencing the Cell Therapy Human Raw Materials Market. As pharmaceutical companies recognize the potential of cell therapies, funding for research and development has increased markedly. Reports indicate that investments in biopharmaceuticals have reached record levels, with billions allocated to innovative therapies, including cell-based treatments. This influx of capital is likely to accelerate the development of new products and technologies, thereby expanding the market for human raw materials used in cell therapies. Furthermore, partnerships between biopharmaceutical companies and research institutions are fostering innovation, which may lead to the introduction of novel therapies. The Cell Therapy Human Raw Materials Market is thus poised for growth, driven by this robust financial backing and the ongoing quest for effective treatment solutions.

### Increased Focus on Regenerative Medicine

The heightened focus on regenerative medicine is driving the Cell Therapy Human Raw Materials Market. As the medical community seeks to develop therapies that restore or replace damaged tissues and organs, cell therapies are emerging as a viable solution. The regenerative medicine market is projected to grow significantly, with estimates suggesting a valuation of over 100 billion in the next few years. This growth is attributed to advancements in technology and a better understanding of cellular mechanisms. The Cell Therapy Human Raw Materials Market is likely to benefit from this trend, as the demand for high-quality human raw materials increases to support the development of regenerative therapies. Consequently, the intersection of regenerative medicine and cell therapy is expected to create new opportunities for innovation and market expansion.

## Future Outlook

The Cell Therapy Human Raw Materials Market is projected to grow at a 22.6% CAGR from 2025 to 2035, driven by advancements in biomanufacturing and increasing demand for personalized medicine.

**New opportunities:**

- Development of automated cell processing systems for enhanced efficiency.
- Expansion into emerging markets with tailored product offerings.
- Strategic partnerships with biotech firms for innovative raw material sourcing.

By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

## Segment Insights

### By Product: Cell Culture Media (Largest) vs. Growth Factors (Fastest-Growing)

In the Cell Therapy Human Raw Materials Market, the product segmentation reveals significant variances in market share among various components. Cell Culture Media holds a commanding position as the largest segment, catering to the foundational needs of cell cultivation. In contrast, Growth Factors are rapidly gaining traction, fueled by their essential role in enhancing cell growth and differentiation, making them an increasingly vital component in modern therapies.

Cell Culture Media (Dominant) vs. Growth Factors (Emerging)

Cell Culture Media has established itself as the dominant player within the market, largely due to its critical function in providing the necessary nutrients and environment for cell proliferation. This segment is characterized by a diversity of formulations tailored for various cell types, ensuring optimal growth conditions. Conversely, Growth Factors represent an emerging segment, distinguished by their potency in driving cellular processes essential for successful cell therapy applications. As research advances, the demand for these factors is surging, positioning them as a key driver for innovation in therapeutic developments.

### By End-Use: Biopharmaceutical & Pharmaceutical Companies (Largest) vs. CROs & CMOs (Fastest-Growing)

In the Cell Therapy Human Raw Materials Market, the distribution of market share across end-use segments reveals that Biopharmaceutical & Pharmaceutical Companies command the largest share, owing to their extensive investments in research and development of cell therapies. This segment is driven by the rising demand for advanced therapies aimed at chronic diseases. In contrast, CROs & CMOs are capturing attention as a fast-growing segment, supported by the increasing trend of outsourcing research and manufacturing processes, leading to a significant rise in their market presence.

Biopharmaceutical & Pharmaceutical Companies (Dominant) vs. CROs & CMOs (Emerging)

Biopharmaceutical & Pharmaceutical Companies play a dominant role in the Cell Therapy Human Raw Materials Market, leveraging their vast resources and advanced technological capabilities to develop innovative cell-based therapies. Their established infrastructure and intellectual property positions them favorably, allowing for accelerated development timelines. Meanwhile, CROs & CMOs are emerging as critical players, providing specialized services that enable biopharmaceutical firms to optimize costs and enhance efficiency. These organizations are increasingly sought after for their expertise in the processing and storage of raw materials, thereby contributing significantly to the overall growth of the sector.

## Regional Market Share Analysis

### North America : Innovation and Investment Hub

North America dominates the Cell Therapy Human Raw Materials market, accounting for approximately 45% of the global share. The region's growth is driven by significant investments in biotechnology, a robust healthcare infrastructure, and increasing demand for advanced therapies. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring a conducive environment for innovation and development. The United States is the largest market, followed by Canada, which is rapidly emerging as a key player. Major companies such as Thermo Fisher Scientific and Cytiva are headquartered here, contributing to a competitive landscape that fosters collaboration and technological advancements. The presence of leading research institutions also enhances the region's capabilities in cell therapy development.

### Europe : Regulatory Framework and Growth

Europe is witnessing a significant rise in the Cell Therapy Human Raw Materials market, holding about 30% of the global share. The region benefits from a strong regulatory framework that encourages innovation while ensuring patient safety. The European Medicines Agency (EMA) has been pivotal in streamlining approval processes, which has led to increased investments in research and development across member states. Germany and the UK are the leading countries in this market, with a growing number of biotech firms and research institutions focusing on cell therapies. Key players like Merck KGaA and Miltenyi Biotec are actively involved in advancing technologies and products. The competitive landscape is characterized by collaborations between academia and industry, fostering a vibrant ecosystem for cell therapy advancements.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is emerging as a significant player in the Cell Therapy Human Raw Materials market, accounting for approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditures, a rising prevalence of chronic diseases, and supportive government initiatives aimed at enhancing biopharmaceutical capabilities. Countries like Japan and China are at the forefront, driving demand for advanced therapeutic solutions. Japan leads the market, with a strong focus on regenerative medicine and cell therapy research. China is rapidly catching up, supported by government funding and a growing number of biotech firms. Key players such as Fujifilm Diosynth Biotechnologies are expanding their operations in the region, contributing to a competitive landscape that is increasingly attracting global investments and partnerships.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually developing its Cell Therapy Human Raw Materials market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments, rising awareness of advanced therapies, and a focus on improving healthcare infrastructure. Countries like South Africa and the UAE are leading the way, with initiatives aimed at enhancing biopharmaceutical capabilities and regulatory frameworks. South Africa is emerging as a key player, with several research institutions and biotech firms focusing on cell therapy innovations. The competitive landscape is still in its nascent stages, but there is a growing interest from international companies looking to enter the market. Local players are also beginning to collaborate with The Cell Therapy Human Raw Materials reach.

## Competitive Benchmarking

The Cell Therapy Human Raw Materials Market is characterized by a dynamic competitive landscape, driven by increasing demand for advanced therapeutic solutions and a growing emphasis on personalized medicine. Key players such as Lonza (CH), Thermo Fisher Scientific (US), and Merck KGaA (DE) are strategically positioned to leverage their extensive portfolios and technological capabilities. Lonza (CH) focuses on enhancing its manufacturing capabilities, particularly in cell and gene therapy, while Thermo Fisher Scientific (US) emphasizes innovation through its comprehensive product offerings and digital solutions. Merck KGaA (DE) is actively pursuing partnerships to expand its reach in the biopharmaceutical sector, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven.
The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production facilities to reduce lead times and enhance responsiveness to regional demands. This tactic not only improves operational efficiency but also strengthens relationships with local clients, thereby fostering a more resilient supply chain. The collective influence of these key players is significant, as they drive advancements in technology and operational excellence, which are crucial for maintaining competitive advantage.
In August 2025, Lonza (CH) announced the expansion of its cell and gene therapy manufacturing facility in Houston, Texas. This strategic move is expected to enhance its production capacity and meet the rising demand for cell therapies in North America. By investing in state-of-the-art technology and increasing its footprint in a key market, Lonza positions itself to better serve its clients and capitalize on growth opportunities in the region.
In September 2025, Thermo Fisher Scientific (US) launched a new suite of digital solutions aimed at streamlining the development and manufacturing processes for cell therapies. This initiative underscores the company's commitment to innovation and reflects a broader trend towards digital transformation in the industry. By integrating advanced analytics and automation into its offerings, Thermo Fisher Scientific enhances its value proposition, potentially leading to improved customer satisfaction and loyalty.
In July 2025, Merck KGaA (DE) entered into a strategic partnership with a leading biotechnology firm to co-develop next-generation cell culture media. This collaboration is indicative of the growing trend towards strategic alliances in the sector, as companies seek to combine expertise and resources to accelerate product development. Such partnerships not only enhance innovation but also allow for shared risk, which is particularly valuable in the rapidly evolving landscape of cell therapy.
As of October 2025, current competitive trends in the Cell Therapy Human Raw Materials Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the need for collaboration to navigate the complexities of the market. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in an increasingly competitive environment.

## Recent News & Developments

- **Q2 2024: FUJIFILM Irvine Scientific Expands Cell Culture Media Manufacturing Facility in the Netherlands** FUJIFILM Irvine Scientific announced the opening of a new cell culture media manufacturing facility in Tilburg, Netherlands, to support the growing demand for raw materials in cell therapy and regenerative medicine applications.
- **Q2 2024: Lonza Opens New Cell and Gene Therapy Manufacturing Facility in Houston** Lonza inaugurated a new state-of-the-art manufacturing facility in Houston, Texas, dedicated to the production of cell and gene therapy raw materials, aiming to increase capacity for clinical and commercial supply.
- **Q2 2024: Thermo Fisher Scientific Launches Gibco CTS DynaCellect Magnetic Separation System for Cell Therapy Manufacturing** Thermo Fisher Scientific introduced the Gibco CTS DynaCellect Magnetic Separation System, a new product designed to streamline cell therapy manufacturing workflows by improving the separation and processing of human cells.
- **Q3 2024: Bio-Techne Announces Launch of GMP-Grade Recombinant Human Cytokines for Cell Therapy Applications** Bio-Techne launched a new line of GMP-grade recombinant human cytokines, expanding its portfolio of raw materials for use in the manufacturing of cell therapies.
- **Q3 2024: Cytiva and Forecyte Bio Announce Strategic Partnership to Advance Cell Therapy Manufacturing in China** Cytiva and Forecyte Bio entered a strategic partnership to co-develop and supply critical raw materials and technologies for cell therapy manufacturing in the Chinese market.
- **Q3 2024: Sartorius Acquires CellGenix to Strengthen Cell Therapy Raw Materials Portfolio** Sartorius completed the acquisition of CellGenix, a leading supplier of GMP-grade raw materials for cell and gene therapies, to enhance its offerings in the cell therapy sector.
- **Q4 2024: Merck KGaA Invests €100 Million in New Cell Therapy Raw Materials Facility in Switzerland** Merck KGaA announced a €100 million investment to build a new facility in Switzerland dedicated to the production of high-quality raw materials for cell therapy manufacturing.
- **Q4 2024: Miltenyi Biotec Opens Expanded GMP Manufacturing Site for Cell Therapy Reagents in Germany** Miltenyi Biotec opened an expanded GMP manufacturing site in Bergisch Gladbach, Germany, to increase production capacity for cell therapy reagents and raw materials.
- **Q1 2025: Avantor Acquires Cell Solutions Provider BioIVT to Expand Cell Therapy Raw Materials Business** Avantor acquired BioIVT, a provider of biological specimens and cell-based products, to strengthen its position in the cell therapy raw materials market.
- **Q1 2025: Thermo Fisher Scientific Launches GMP-Grade Human Platelet Lysate for Cell Therapy Manufacturing** Thermo Fisher Scientific introduced a new GMP-grade human platelet lysate product, designed to support the expansion and manufacturing of human cell therapies.
- **Q2 2025: Catalent Announces $200 Million Expansion of Cell Therapy Raw Materials Production in Maryland** Catalent announced a $200 million investment to expand its cell therapy raw materials production capabilities at its facility in Maryland, aiming to meet increasing demand from biopharma clients.
- **Q2 2025: Wuxi AppTec Opens New Cell Therapy Raw Materials Manufacturing Facility in Shanghai** Wuxi AppTec opened a new manufacturing facility in Shanghai dedicated to the production of raw materials for cell therapy, expanding its global supply network.

## Report Scope

| MARKET SIZE 2024 | 5.344(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.552(USD Billion) |
| MARKET SIZE 2035 | 50.28(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 22.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Lonza (CH), Thermo Fisher Scientific (US), Merck KGaA (DE), Fujifilm Diosynth Biotechnologies (JP), Cytiva (US), Miltenyi Biotec (DE), STEMCELL Technologies (CA), Bristol-Myers Squibb (US) |
| Segments Covered | Product, End-User, Region |
| Key Market Opportunities | Advancements in bioprocessing technologies enhance efficiency in the Cell Therapy Human Raw Materials Market. |
| Key Market Dynamics | Rising demand for innovative cell therapies drives competition and regulatory scrutiny in the human raw materials market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Cell Therapy Human Raw Materials Market?**
A: The market valuation was 5.344 USD Billion in 2024.

**Q: What is the projected market size for the Cell Therapy Human Raw Materials Market by 2035?**
A: The market is projected to reach 50.28 USD Billion by 2035.

**Q: What is the expected CAGR for the Cell Therapy Human Raw Materials Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 22.6%.

**Q: Which companies are considered key players in the Cell Therapy Human Raw Materials Market?**
A: Key players include Lonza, Thermo Fisher Scientific, Merck KGaA, and others.

**Q: What segment contributed the most to the market valuation in 2024?**
A: Cell Culture Sera contributed 1.2 USD Billion to the market valuation in 2024.

**Q: How much is the Cell Culture Media segment projected to grow by 2035?**
A: The Cell Culture Media segment is projected to grow to 7.5 USD Billion by 2035.

**Q: What is the expected market size for Biopharmaceutical & Pharmaceutical Companies by 2035?**
A: This segment is expected to reach 25.0 USD Billion by 2035.

**Q: What role do Academic & Research Institutions play in the market?**
A: They contributed 1.344 USD Billion in 2024 and are projected to grow significantly.

**Q: How does the market for Growth Factors compare to other segments?**
A: The Growth Factors segment was valued at 0.4 USD Billion in 2024 and is expected to grow.

**Q: What is the significance of CROs & CMOs in the Cell Therapy Human Raw Materials Market?**
A: CROs & CMOs contributed 1.5 USD Billion in 2024 and are projected to grow to 15.0 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cell-therapy-human-raw-materials-market-21539*